The generic opioid manufacturer that filed for bankruptcy twice over addiction litigation controls the only supply of Acthar Gel, extracted from pig pituitary glands and used to treat infantile spasms and MS relapses. When Mallinckrodt entered Chapter 11 again in August 2023, infants dependent on the drug faced immediate supply uncertainty from the same company prosecutors had targeted for opioid practices.
Source: Mallinckrodt Will Pay $100 Million to Settle FTC, State Charges It Illegally Maintained its Monopoly of Specialty Drug Used to Treat Infants · Federal Trade Commission · Jan 18, 2017